Filtronic PLC's shares rose nearly 14% following a record $68.1 million order from SpaceX for its Cerus E-band gallium nitride power amplifiers, expected to be fulfilled in 2028. This order supports Cavendish's 'buy' rating and 290p price target, covering over 90% of Filtronic's projected 2028 revenue. The contract highlights growing demand for Filtronic's technology in SpaceX's Starlink ground stations, with potential expansion into other satellite and defense markets. Cavendish maintains its 2028 revenue forecast of £75 million and adjusted EBITDA of £17 million, anticipating continued SpaceX investment beyond 2028.
Filtronic's shares jumped 14% after a major SpaceX order, providing context for readers interested in technology stocks. For readers following the technology sector, here is Pluang's market snapshot as of Oct 01, 2026 14:21 WIB: Of 150 US tech stocks on Pluang, 94 rose and 50 fell. Among notable movers, LRCX rose 2.64% with a typical hold time of 60 days and a buy order activity of 62%, contrasting with AMAT which increased 2.47% but had 73% sell orders, while UMC gained 2.57% with a shorter hold time of 42 days and more sell orders at 62%.
A webinar titled "Ready for AI?" scheduled for October 29, 2026, will discuss how artificial intelligence is reshaping public relations by changing how information is found, evaluated, and shared. Experts will share insights on maintaining message vi...
17a-4 LLC introduced DataParser Hub, an API that enables clients to integrate proprietary messaging and collaboration data into Microsoft 365 Purview and Copilot. This solution supports over 30 data types from platforms like Slack, Zoom, and Webex, a...
IBA has treated the first patient in the C-FLASH-01 clinical trial, the first human study testing ConformalFLASH® proton therapy. This trial, conducted at Penn Medicine with FDA approval, explores the feasibility of using ultra-high dose rate proton ...
IBA has treated the first patient in the C-FLASH-01 clinical trial, testing its ConformalFLASH® proton therapy for head and neck cancer re-irradiation. This trial, led by Penn Medicine and approved by the FDA, explores ultra-high dose rate proton the...
WISeQey Corp. completed its redomiciliation and began trading on Nasdaq and the SIX Swiss Exchange, marking a new phase focused on integrating its quantum cybersecurity, digital identity, and space IoT technologies. Its subsidiary WISeSat.Space also ...
